Utah Medical Products Inc. logo

Utah Medical Products Inc. (UTMD)

Market Closed
3 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
65. 53
-1.29
-1.93%
$
208.68M Market Cap
14.7 P/E Ratio
1.2% Div Yield
8,117 Volume
0 Eps
$ 66.82
Previous Close
Add Transaction
Day Range
65.36 68
Year Range
52 71.81
Want to track UTMD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Utah Medical Products, Inc. Announces Quarterly Dividend

Utah Medical Products, Inc. Announces Quarterly Dividend

SALT LAKE CITY, UT / ACCESSWIRE / August 2, 2024 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on October 4, 2024 to stockholders of record at the close of business on September 20, 2024. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.

Accesswire | 1 year ago
Utah Medical (UTMD) Q2 EPS Falls Y/Y on Lower Key Customer Sales

Utah Medical (UTMD) Q2 EPS Falls Y/Y on Lower Key Customer Sales

Utah Medical (UTMD) reports a 19.2% revenue decline in 2Q24, with EPS down 15.3% due to lower sales to major customers. Despite this, profit margins remained stable.

Zacks | 1 year ago
UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2024

UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2024

SALT LAKE CITY, UT / ACCESSWIRE / July 25, 2024 / As previously projected, Utah Medical Products, Inc. (Nasdaq:UTMD) realized second calendar quarter (2Q) and first half (1H) 2024 financial results which reflect a substantial decline in revenues. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros.

Accesswire | 1 year ago
Zacks Initiates Coverage of UTMD With Neutral Recommendation

Zacks Initiates Coverage of UTMD With Neutral Recommendation

Explore why Zacks rates UTMD with a "Neutral" recommendation, being the first on Wall Street to initiate coverage on the stock. Learn about UTMD's financial stability, diverse product portfolio, and market opportunities, balanced against key challenges in the competitive medical device industry.

Zacks | 2 years ago